Cyclic interf eron alpha treatment in metastatic renal cell carcinoma: Results of a phase II study and review of the literature

Urologia Internationalis

Volumn 58, Issue 1, 1997, Pages 8-12

  Hofmockel, Georg ^a   Tack, Winfried ^a   Frohmüller, Hubert G W ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Advanced renal cell carcinoma; Interferon alpha; Response rate

Indexed keywords

ANTINEOPLASTIC AGENT; RECOMBINANT ALPHA2B INTERFERON;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INFLUENZA; KIDNEY CARCINOMA; LUNG METASTASIS; MALE; METASTASIS; NEPHRECTOMY; NEPHROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031040735     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000282937     Document Type: Article

References (34)

1. Taylor JL, Papadimitrou J: Effects of interferons on cell growth and function: in Billau A (cd): Interferon: General and Applied Aspects, New York, Elsevier, 1984, voi 1, p 140.
2. De Riese W, Allhoff E, Kirchner H, Stief CG, Atzpodien J, Maschck H, Jonas U: Complete spontaneous regression in metastatic renal cell carcinoma: An update and review, World J Urol 1991;9:184-191.
3. Bono AV: Steroid hormones and hormonal treatment in renal cell carcinoma; in De Kernion JB, Pavon Macaiuso M (eds): Tumors of Kidney, Baltimore, Williams & Wilkins, 1986, vol 13, pp 205-227.
4. De Kcrnion JB: Treatment of advanced renal cell carcinoma: Traditional methods and innovative approaches, J Urol 1983;130:2-7.
5. Wirth MP: Immunotherapy for metastatic renal cell carcinoma, Urol Clin North Am 1993; 20:283-295.
6. Dc Kcrnion JB, Sarna G, Figlili R, Lindner A, Smith RB: The treatment of renal cell carcinoma with human leukocyte alpha-interferon, J Urol 1982:130:1063-1066.
7. Quesada JR, Swanson DA, Trindadc A, Gut-tcrman JU: Renal cell carcinoma: Antitumor effects of leukocyte interferon, Cancer Res 1983:43:940-947.
8. Krown SE, Einzig A, Abramson JD, Octtgcn HF: Treatment of advanced renal cell cancer (RCC) with recombinant leukocyte A interferon (rIFN-uA), Proc Am Soc Clin Oncol 1983:2: 58.
9. Einzig AI, Krown SF, Oettgen HF: Recombinant leukocyte A interferon (rIFN-aa) in renal cell cancer (RCC), Proc Am Soc Clin Oncol 1984:3:54.
10. Quesada JR, Rios A, Swanson DA, Trown P, Gutterman JU: Antitumor activity of recombi-nant-dcrivcd interferon alpha (rIFNaA) in metastatic renal cell carcinoma, J Clin Oncol 1985:3:1522-1528.
11. Umcda T, Niijima T: Phase II study of alpha interferon on renal cell carcinomas, Cancer 1986;58:1231-1235.
12. Schnall SF, Davis C, Ziyadeh T, Kirkwood JM, Paqualc D, Bobrow S, Schnippcr E, Erstoff MS: Treatment of mestastatic renal cell carcinoma (RCC) with intramuscular (IM) recombinant interferon alpha A (IFN, Hoffmann-La Roche), Proc Am Soc Clin Oncol 1986;5:227.
13. Kempf RA, Grunberg SM, Daniels JR, Skinner DG, Venturi CL, Spiegel R, Neri RL, Greiner JM, Rudnick S, Mitchell MS: Recombinant interferon a-2 (Intron A) in a phase II study of renal cell carcinoma, J Biol Response Modif 1986;5:27-35.
14. Sarna G, Figlin R, De Kernion J: Interferon in renal cell carcinoma: The UCLA experience, Cancer 1987;59:610-612.
15. Muss HB, Costanzi JJ, Leavitt R, Williams RD, Kcmpf RA, Pollard R, Ozcr H, Zckan PJ, Grunberg SM, Mitchell MS, Caponcra M, Ga-vigan M, Ernest ML, Venturi C, Greiner J, Spiegel RJ: Recombinant alpha interferon in renal cell carcinoma: A randomized trial of two routes of administration, J Clin Oncol 1987;5: 286-291.
16. Otto U, Schneider A, Denkhaus H, Conrad S: Die Behandlung des metastasierten Nierenkarzinoms mit rekombinantem alpha-2 oder gam-ma-Interfcron: Ergebnisse zweier klinischer Phasc-11-bzw.-111-Studicn, Onkologie 1988; 11:185-191.
17. Levens W, Ruebben H, Ingenhag W: Longterm interferon in metastatic renal cell carcinoma, EurUrol 1989;16:378-381.
18. Marshall ME, Simpson W, Butler K, Fried A, Fer M: Treatment of renal cell carcinoma with daily low-dose alpha interferon, J Biol Response Modif 1989:8:453-461.
19. Steineck G, Strander H, Carbin BE, Borgström E, Wallin L, Achtnich U, Arvidsson A, Söderlund V, Näslund I, Esposti PL, Norell SE: Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinomas, Acta Oncol 1990;29:155-162.
20. Bono AV, Reali L, Benvenuti C, Rigatti P, Gib-ba A, Cosciani-C'unico S, Brausi M, Vicini D, Pavone-Macaluso M, Ansclmo G, Coppi F, Franch L: Recombinant alpha interferon in metastatic renal cell carcinoma, Urology 1991; 38:60-63.
21. Creagan ET, Twito DI, Johansson SL, Schaid DJ, Johnson PS, Flaum MA, Buroker TR, Gceraerts LH, Veedcr MH, Gesmc DH, Hom-burger HA: A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma, J Clin Oncol 1991:9:2104-2109.
22. Kosntidis PA, Baxevanis CN, Tsavaris N, Pa-pananastasiou M, Anastasopoulos E, Bacoyian-nis C, Mylonakis N, Karvounis N, Bafaloukos D, Karabelis A: The prognostic significance of immune changes in patients with renal cell carcinoma treated with interfcron-alpha-2b, J Clin Oncol 1992:10:1153-1157.
23. Merimsky O, Chaitchik S: Our experience with interferon alpha: Renal cell carcinoma, Mol Biothcr 1992:4:130-134.
24. Abratt RP, Pontin AR, Ball HS: Activity of a short course of interferon alpha for metastatic renal cell carcinoma: A phase-2 study, Cancer Immunol Immunothcr 1993;37:140-141.
25. Tsavaris N, Mylonakis N, Bacoyiannis C, Tsoutsos H, Karabelis A, Kosmidis P: Treatment of renal cell carcinoma with escalating doses of alpha interferon, Chemotherapy 1993: 39:361-366.
26. De Mulder PH, Oosterhof G, Bouffioux C, van Oosterom AT, Vermeylen K, Sylvester R for the EORTC Genitourinary Group: Randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma, Br J Cancer 1995:71:371-375.
27. Lacobelli S, Garufi C, Irtclli L, Martino MT, Santabuono F, Vicario G, Tinari N, Fiorentino B, Innoccnti P, Natoli C: A phase I study of recombinant intcrfcron-alpha administered as a seven-day continuous venous infusion at cir-cadian-rhythm-modulated rate in patients with cancer, Am J Clin Oncol 1995; 18:27-31.
28. Rosenberg SA, Lotzc MT, Muul LM, Chang AE, Avis FP, Leitman WM, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE: A progress report on the treatment of 157 patients with advanced cancer using lymphokinc-activated killer cells and interleukin-2 or high-dosc intcrlcukin-2 alone, N Engl J Med 1987;316:889-897.
29. Koisc K for the Recombinant Human Interferon Gamma (S-6810) Research Group on Renal Cell Carcinoma: Phase II study of recombinant human interferon gamma (S-6810) on renal cell carcinoma, Cancer 1987:60:929-933.
30. Bclldegrun A, Figlin R, Haas G, dc Kent ion J: Immunotherapy for metastatic renal-cell carcinoma, World J Urol 1991;9:157-159.
31. Racklcy R, Novick A, Klein E, Bukowski R, McLain D, Goldfarb D: The impact of adjuvant nephrectomy on multimodality treatment of metastatic renal cell carcinoma, J Urol 1994; 152:1399-1403.
32. Nanus DM, Pfeffer LM, Bander NH, Bahri S, Albino AP: Antiproliferative and antitumor effects of alpha-interfcron in renal cell carcinomas: Correlation with the expression of a kidney-associated differentiation glycoprotein, Cancer Res 1990:5:4190-4194.
33. Fossa SD, Lehne G, Gunderson R, Hjelmas U, Holdencr EE: Recombinant interferon alpha-2A combined with prednisone in metastatic renal cell carcinoma: Treatment results, serum interferon levels and the development of antibodies, Int J Cancer 1992:50:868-870.
34. Bassukas ID, Hofmockel G, Maurcr-Schultzc B: Treatment with tumor necrosis factor a and interferon a of a human kidney cancer xenograft in nude mice: Evidence for an anticachec-tic effect of interferon a, Anticancer Res 1994; 14:237-246.s